Clinical and pathological features associated with chromophobe renal cell carcinoma recurrence: analysis from a nationwide cohort (UroCCR-136)
We studied a rare kidney cancer type, called chromophobe renal cell carcinoma (chRCC), to understand why some patients experience recurrence. We found that being male, having advanced disease, or some aggressive pathological characteristics increased the risk of cancer coming back. Our results suggest that doctors should monitor certain patients more closely after surgery. This research may help improve long-term follow-up and treatment plans for patients with chRCC. While certain factors are associated with a higher risk of recurrence, it is important to note that chromophobe renal cell carcinoma generally has a favourable prognosis, and the absolute risk of recurrence remains low for most patients.
Authors
- Alexis Fontenil
- Louis Vignot (ORCID: https://orcid.org/0000-0002-6826-3590)
- J. Guillotreau
- Jean‐Baptiste Beauval (ORCID: https://orcid.org/0000-0002-1532-015X)
- Marc‐Olivier Timsit (ORCID: https://orcid.org/0000-0002-5605-2956)
- N. Branger (ORCID: https://orcid.org/0000-0003-3034-2928)
- Édouard Auclin (ORCID: https://orcid.org/0000-0001-7039-4840)
- Jean‐Christophe Bernhard (ORCID: https://orcid.org/0000-0001-8564-1699)
- Bastien Parier
- Frédéric Panthier (ORCID: https://orcid.org/0000-0003-3055-2984)
- Pierre Bigot (ORCID: https://orcid.org/0000-0002-5669-9020)
- Arthur Peyrottes (ORCID: https://orcid.org/0000-0003-1158-0082)
- F. Bruyère
- Constance Michel (ORCID: https://orcid.org/0000-0001-8826-8797)
- Z. Khene (ORCID: https://orcid.org/0000-0002-4124-789X)
- N. Doumerc (ORCID: https://orcid.org/0000-0001-6133-4213)
- Arnaud Méjean (ORCID: https://orcid.org/0000-0003-2280-9516)
- C. Champy
- Fayek Taha
- François Hénon
- Morgan Rouprêt (ORCID: https://orcid.org/0000-0001-8440-7075)
- Sophie Knipper (ORCID: https://orcid.org/0000-0002-2681-3611)
- Laurent Guy (ORCID: https://orcid.org/0000-0001-9561-9356)
- G. Pignot (ORCID: https://orcid.org/0000-0001-5282-9134)
- R. Mallet
- Thibaut Waeckel (ORCID: https://orcid.org/0000-0002-5775-479X)
- G. Fiard (ORCID: https://orcid.org/0000-0003-3049-5318)
- S. Bernardeau
- Louis Surlemont (ORCID: https://orcid.org/0000-0002-1580-9684)
- Jean‐Jacques Patard
Institutions
- Inserm (FR)
- Université Paris Cité (FR)
- Centre Hospitalier Universitaire de Grenoble (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Hospitalier Universitaire Henri-Mondor (FR)
- Centre Hospitalier Universitaire de Toulouse (FR)
- Sorbonne Université (FR)
- Lille’s Cardiology Hospital (FR)
- Centre Hospitalier Universitaire de Tours (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Centre Hospitalier Universitaire de Nîmes (FR)
- Centre Hospitalier Universitaire de Reims (FR)
- Hôpital Européen (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire d'Angers (FR)
- Centre Hospitalier Universitaire de Caen Normandie (FR)
- Hôpital Saint Joseph (FR)
- Pitié-Salpêtrière Hospital (FR)
- Centre Hospitalier Universitaire de Clermont-Ferrand (FR)
- Hôpitaux Universitaires Henri-Mondor (FR)
- Clinique Pasteur (FR)
- Hôpital Saint-Louis (FR)
- Polyclinique de Franche Comté (FR)
- Institut Paoli-Calmettes (FR)
- Centre Hospitalier Universitaire de Rouen (FR)
- Centre Hospitalier Universitaire de Rennes (FR)
- Bicêtre Hospital (FR)
- Hôpital Tenon (FR)
- Onco-Urologie Prédictive
- Université de Rouen Normandie (FR)
- Université de Reims Champagne-Ardenne (FR)
- Université de Caen Normandie (FR)
Publication Details
- Journal
- European Urology Open Science
- Published
- 2025-11-17
- DOI
- https://doi.org/10.1016/j.euros.2025.10.023
- Primary Topic
- Renal cell carcinoma treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00